Accession Therapeutics raises £30.5 million ($40 million USD) to advance TROCEPT immunotherapy platform
- Accession Therapeutics
- Dec 4
- 3 min read
Proceeds will enable generation of full clinical data from ongoing Phase 1 study of TROCEPT-01 (ATTR-01), its lead programme in advanced solid tumours, and progression of TROCEPT-02 (ATTR-02) into the clinic.
Oxford, UK, 4 December 2025 – Accession Therapeutics Limited, a clinical-stage biopharmaceutical company developing next generation cancer immunotherapies announces it has raised £30.5 million ($40 million USD) from its existing investors.
Accession Therapeutics’ tumour-targeted immunotherapy platform, TROCEPT, is designed to activate the immune system in solid tumours that are resistant to conventional treatment. By combining targeted viral delivery with localised immune activation only in tumours, TROCEPT offers a potent, selective and scalable approach.
Proceeds from the financing will be used to advance Accession Therapeutics’ growing pipeline of first-in-class immunotherapies developed using the platform. This includes enabling the Company to generate full clinical data from its ongoing Phase 1 ATTEST study of TROCEPT-01 (ATTR-01), the Company’s lead programme designed to selectively generate a clinically validated checkpoint inhibitor within advanced solid tumours. Funds will also be used to progress TROCEPT-02 into the clinic. This second programme is designed to deliver a proprietary genetically encoded universal bispecific T cell engager into tumours.
Bent Jakobsen, PhD FMedSci, Chief Executive Officer of Accession Therapeutics, said:“This financing reflects the continued strong support of our investors and enables us to take the next important steps in advancing the TROCEPT pipeline. With TROCEPT-01 now in the clinic, and TROCEPT-02 following close behind, we are building momentum towards demonstrating the potential of our tumour-targeted immunotherapy platform.”
Jeff Lin, Partner of iGlobe Partners, said: “We are proud to continue supporting Accession Therapeutics as it advances its innovative TROCEPT platform into the clinic. The company has made remarkable progress in a short period of time, and we believe TROCEPT has the potential to create a new class of immunotherapies for patients with solid tumours.”
Since inception in 2021, the Company has raised nearly USD $100 million from high-net-worth individuals and venture capitalists, including iGlobe Partners, Primavera Venture Partners and Birk Ventures.
– ENDS –
For more information, please contact:
Victoria Foster Mitchell – PR Consultant
Stephanie Bewick – Chief Business Officer
About Accession Therapeutics Limited
Accession Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of tumour-targeted immunotherapies through its proprietary TROCEPT platform. The company is advancing a pipeline of first-in-class therapies designed to transform cancer treatment by enabling localised production of therapeutic proteins within tumours while minimising systemic exposure, potentially offering superior efficacy and safety profiles to existing immuno-oncology approaches.
Since inception in 2021, the Company has raised nearly USD $100 million from high net worth individuals and venture capitalists, including iGlobe Partners, Primavera Venture Partners and Birk Ventures.
For more information, visit www.accessiontherapeutics.com
About TROCEPT-01 (ATTR-01)
The Company’s lead investigational therapy utilises the company’s proprietary TROCEPT platform to deliver a genetically encoded immune checkpoint inhibitor (anti-PD-L1) directly to tumour cells. This innovative approach enables cancer cells to locally produce and secrete therapeutic proteins within the tumour microenvironment, creating a potent anti-tumour response while minimising systemic exposure. Unlike conventional immunotherapies administered systemically, TROCEPT-01’s tumour-targeted mechanism has demonstrated in preclinical studies the potential to enhance drug concentration at the tumour site compared to healthy tissues, significantly improving the therapeutic window. The therapy is designed to overcome limitations of current checkpoint inhibitors by increasing response rates in immunologically "cold" tumours and reducing off-target immune-related adverse events. Administered intravenously, TROCEPT-01 represents a promising new modality in cancer treatment, with potential applications across multiple solid tumour types.
About TROCEPT-02 (ATTR-02)
TROCEPT-02 utilises the company’s TROCEPT platform to deliver a genetically encoded and proprietary universal bispecific T cell engager through intravenous administration which, like TROCEPT-01 will infect tumour cells, not normal cells. TROCEPT-02 is also targeted to αvβ6 integrin so will address many solid tumour indications. The universal bispecific payload, which will be produced by the tumour cells, has the potential to address the heterogeneity of cancer cells in that it will kill all tumour cells rather than edit the tumour and produce a result akin to ‘pharmaceutical surgery’. It is currently in preclinical development.